Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 0.650-0.700 for the period, compared to the consensus EPS estimate of 0.710. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $2.9 billion.

Amneal Pharmaceuticals Stock Up 3.5 %

Shares of NASDAQ AMRX opened at $8.67 on Friday. The company’s 50-day simple moving average is $8.10 and its 200-day simple moving average is $8.32. Amneal Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $9.48. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of -12.75 and a beta of 1.10.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMRX. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Piper Sandler boosted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $10.60.

Insiders Place Their Bets

In other news, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the transaction, the director now owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold 160,000 shares of company stock worth $1,292,000 in the last 90 days. Corporate insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.